Biodesix INC

Biodesix, Inc. announced robust second quarter 2026 financial results, featuring a 34% increase in total revenue to $26.9 million and a 42% surge in Diagnostic Testing revenue.

Biodesix, Inc. held its 2026 annual meeting, where stockholders elected two Class III directors, approved executive compensation on an advisory basis, and ratified KPMG LLP as the independent auditor.

Biodesix, Inc. announced robust first quarter 2026 financial and operating results, driven by significant growth in both Diagnostic Testing and Development Services, leading to an increase in full-year revenue guidance.

Biodesix, Inc. announced strong fourth quarter and fiscal year 2025 results, surpassing revenue guidance and achieving its first quarter of positive Adjusted EBITDA.

Biodesix, Inc. announced preliminary unaudited financial results for Q4 and full-year 2025, reporting strong revenue growth and affirming Adjusted EBITDA positivity for Q4.

Biodesix, Inc. reported a robust third quarter with 20% revenue growth and improved gross margins, leading to an increased full-year 2025 revenue guidance.

Biodesix, Inc. reported a 20% increase in total revenue for the third quarter of 2025, driven by strong growth in both diagnostic tests and development services, while also narrowing its net loss.

Biodesix, Inc. reported a 12% increase in second-quarter revenue, driven by strong growth in diagnostic tests and development services, but faces a Nasdaq delisting notice and increased net loss for the quarter.

Biodesix reports a 21% increase in revenue for Q1 2025 and secures an additional $10 million loan while addressing Nasdaq compliance.

Biodesix, a lung disease diagnostics company, announced a 35% year-over-year revenue increase in the third quarter of 2024, primarily driven by strong growth in its lung diagnostic testing segment.

Biodesix's Q2 2024 revenue increased by 51% year-over-year, fueled by growth in both lung diagnostic testing and biopharmaceutical services.

Biodesix's first quarter 2024 results show a significant 64% increase in total revenue, driven by growth in both lung diagnostic testing and biopharmaceutical services.

Biodesix, Inc. announced a 24% increase in total revenue for fiscal year 2025, reaching $88.5 million, driven by growth in lung diagnostic testing and development services, while also extending its senior secured term loan maturity to November 2028.

Biodesix, Inc. (BDSX) announced a 45% year-over-year increase in total revenue for 2024, reaching $71.3 million, fueled by strong growth in both Lung Diagnostic Testing and Development Services.

Biodesix obtains a limited waiver from lenders regarding financial reporting and revenue targets, while reporting a 28% increase in total revenue for 2023, driven by a 54% surge in lung diagnostic revenue.

Jack W Schuler, a 10% owner of Biodesix Inc, purchased 15,000 shares of common stock on August 12, 2026 for $24.47 per share.

Jack W Schuler, a 10% owner of Biodesix Inc, purchased 27,600 shares of common stock on August 10, 2026.

John Patience, Director and Chairman of Bio-De-Six Inc., reported a transaction involving the acquisition of 1,361 restricted stock units.

John Patience, Director and Chairman of Bio-De-Sign Inc., reported transactions involving restricted stock units and common stock.

Biodesix Chief Development Officer Gary Pestano reported the acquisition of common stock from RSU vesting and subsequent sale of shares to cover tax obligations.

Biodesix Chief Commercial Officer Kieran O'Kane reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Biodesix, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on May 19, 2026, to elect directors, vote on executive compensation, and ratify auditor appointment.

Biodesix is asking stockholders to approve a reverse stock split and an amendment to their employee stock purchase plan at the upcoming 2025 annual meeting.

Biodesix, Inc. will hold its annual meeting of stockholders on May 21, 2024, to vote on director elections, auditor ratification, and stock issuance proposals.

Biodesix is holding its 2024 Annual Meeting of Stockholders on May 21, 2024, to vote on director elections, auditor ratification, and proposals related to Series A Preferred Stock.

Biodesix amends its registration statement to facilitate the resale of up to 30.4 million common shares by selling stockholders after the conversion of Series A Preferred Stock.

Biodesix files an S-1 registration for the resale of common stock by selling stockholders and details executive severance agreements.

Jack W. Schuler, an emeritus director of Biodesix Inc., increased his beneficial ownership in the company to 24.0% through recent open market purchases.

Jack W. Schuler, a significant insider, increased his beneficial ownership in Biodesix Inc. to 27.0% following recent share purchases and a reverse stock split.

Jack W. Schuler, a significant shareholder of Biodesix Inc., increased his beneficial ownership to 26.0% by purchasing an additional 3.49 million shares.

Jack W. Schuler, along with his associated trusts, has significantly increased his beneficial ownership in Biodesix Inc. to approximately 24.7% of outstanding shares through recent open market purchases.

Soleus Capital Master Fund, L.P. and affiliated entities have reported beneficial ownership of 5.1% of Biodesix Inc. common stock.

Perceptive Advisors and affiliated entities have filed a Schedule 13G reporting a 4.6% beneficial ownership stake in Biodesix, Inc.

Soleus Capital Master Fund and affiliated entities have filed a Schedule 13G reporting a 4.1% beneficial ownership stake in Biodesix, Inc.

AIGH Capital Management LLC and affiliated entities report beneficial ownership of 7.7% of Biodesix, Inc. common stock as of March 31, 2026.

Telemark Asset Management, Telemark Fund, and Colin McNay jointly report a 5.4% beneficial ownership in Biodesix, Inc. common stock.

Telemark Asset Management and affiliates have filed an exit Schedule 13G/A, reporting their beneficial ownership in Biodesix, Inc. has fallen to 4.1%.